Nutaria

Nutaria, a nutraceutical R&D company, has revolutionized drug delivery with its targeted delivery system to address the shortcomings of traditional "neuro-protective" options for brain health. While nootropic supplements often fail due to low absorption and bioavailability, Nutaria's approach utilizes food molecules as natural "taxis" to deliver active ingredients directly to specific tissues or organs, ensuring improved internalization and effectiveness of therapeutic agents. This patented technology, composed entirely of FDA and EFSA-approved food ingredients, is designed to improve the lives of people with neurodegenerative conditions by focusing on early treatment and prevention, limiting the impact of these medical conditions. Currently, Nutaria is in the advanced preclinical stages of developing a drug specifically for early Parkinson's disease, underscoring their commitment to pioneering treatments that offer hope and improved quality of life for patients.

Nutaria has raised $300K in total funding across 1 rounds. The company is currently at the Pre-Seed stage.

Nutaria operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, with core technologies in Materials & Substances. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Providers.

Nutaria is based in Gav-Yam Negev Advanced Technologies Park, Be'er Sheva, Israel, South District.